ClinicalTrials.gg
CompletedNCT05606965Updated Nov 24, 2025

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

A Phase 2 interventional study of mRNA-1010 and Egg-based Quadrivalent Influenza Vaccine in Influenza, sponsored by ModernaTX, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
11th of 12
172 · median 471
Started
2022
with 5 others
Phase 2
2 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 11th largest by enrollment, is one of 6 that started in 2022, is one of 2 in phase 2, and was the 7th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.

Read the detailed description

The study consists of 3 parts. Part A of the study was conducted for the 2022-23 influenza season. Part B of the study was conducted in 2023-24 influenza season. Part C of the study will be conducted in 2024-25 influenza season.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • mRNA-1010
  • Influenza Vaccine
  • Moderna
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-50 years (Study Parts A, B, and C) and 65-80 years (Study Parts A and B only) of age at the time of consent (Screening Visit).
  • Part A only: (BMI) of 18 kilograms (kg)/meter (m)\^2 to \< 40 kg/m\^2 at the Screening Visit. There will be no BMI requirement for inclusion in Part B and Part C.
  • A person of (POCBP): has a negative highly sensitive pregnancy test at the Screening Visit and before each administration of study intervention; must use a method that is highly effective from at least 28 days prior to Day 1 (Baseline) to at least 3 months after the last study intervention; and is not currently pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Acutely ill or febrile (temperature ≥ 38.0°Celsius (C)/100.4° Fahrenheit (F) hours before or at the D1 vaccination visit. Participants meeting this criterion may be rescheduled within the 28-day screening window.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Reported history of congenital or acquired immunodeficiency, immunocompromizing or condition, asplenia, or history of recurrent severe infections. Certain immune-mediated conditions that are stable and well-controlled (for example, Hashimoto's thyroid disease) or that do not require systemic immunosuppressive therapy may be permitted at the discretion of the Investigator.
  • Dermatologic conditions that could affect local solicited AR assessments (tattoos, psoriatic patches or vitiligo affecting skin over the deltoid injection site area).
  • Has received systemic immunosuppressants (for ≥ 10 mg/day of prednisone or equivalent) for > 14 days in total within 180 days before vaccination visit (D1) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed.
  • Has received systemic immunoglobulins or long-acting biological therapies that may suppress or alter immune responses (for example, Infliximab®) or blood products within 90 days before the vaccination visit or plans to receive them during the study.
  • Has a history of anaphylaxis or severe reaction after receipt of any mRNA or influenza vaccines or any components of the mRNA or influenza vaccines, including egg protein.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Parts A and B - Arm 1: mRNA-1010 (Age Group 18-50 years)

    Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Parts A and B - Arm 2: Egg-based Quadrivalent Influenza Vaccine (Age Group 18-50 years)

    Participants will receive a single dose of egg-based quadrivalent influenza vaccine by IM injection on Day 1.

    Biological: Egg-based Quadrivalent Influenza Vaccine

  • Active comparator
    Parts A and B - Arm 3: Adjuvanted Quadrivalent Influenza Vaccine (Age Group 65-80 years)

    Participants will receive a single dose of adjuvanted quadrivalent influenza vaccine by IM injection on Day 1.

    Biological: Adjuvanted Quadrivalent Influenza Vaccine

  • Active comparator
    Parts A and B - Arm 4: Inactivated Influenza Vaccine (Age Group 65-80 years)

    Participants will receive a single dose of inactivated influenza vaccine by IM injection on Day 1.

    Biological: Inactivated Influenza Vaccine

  • Experimental
    Parts A and B - Arm 5: mRNA-1010 (Age Group 65-80 years)

    Participants will receive a single dose of mRNA-1010 by IM injection on Day 1.

    Biological: mRNA-1010

  • Experimental
    Part C - Arm 1: mRNA-1010 and mRNA-1345 (Age Group 18-50 years)

    Participants will receive one dose of mRNA-1010 concomitantly injected with one dose of mRNA-1345 in the contralateral arm at Day 1.

    Biological: mRNA-1010 · Biological: mRNA-1345

  • Experimental
    Part C - Arm 2: mRNA-1010 and mRNA-1345 (Age Group 18-50 years)

    Participants will receive one dose of mRNA-1010 at Day 1 followed by one dose of mRNA-1345 in the contralateral arm at Day 29.

    Biological: mRNA-1010 · Biological: mRNA-1345

  • Experimental
    Part C - Arm 3: mRNA-1045 (Age Group 18-50 years)

    Participants will receive a single dose of mRNA-1045 by IM injection on Day 1.

    Biological: mRNA-1045

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

  • Sterile suspension for injection

    Also known as: Fluarix®

  • BiologicalAdjuvanted Quadrivalent Influenza Vaccine

    Sterile injectable emulsion

    Also known as: Fluad®

  • BiologicalInactivated Influenza Vaccine

    Sterile suspension for injection

    Also known as: Fluzone®

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalmRNA-1045

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Parts A, B, and C: Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Time frame: Up to Day 7 (7 days after vaccination)

  2. Parts A, B, and C: Number of Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 28 (28 days after vaccination)

  3. Parts A, B, and C: Number of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically Attended Adverse Events (MAAEs), and AEs Leading to Discontinuation

    Time frame: Day 1 through Day 181

  4. Parts A, B, and C: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay

    Time frame: Day 29

  5. Part C: GMT of Anti-Respiratory Syncytial Virus (RSV) Antibodies at Day 29, as Measured by Microneutralization Assay for RSV A and B

    Time frame: Day 29

  6. Parts A, B, and C: Geometric Mean Fold Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay

    Time frame: Baseline, Day 29

  7. Part C: GMFR of Anti-RSV Antibodies at Day 29, as Measured by Microneutralization Assay

    Time frame: Baseline, Day 29

  8. Parts A, B, and C: Percentage of Participants with Seroresponse at Day 29, as Measured by HAI Assay

    Seroresponse is defined as a Day 29 titer \> 1:40 if baseline is \< 1:10 or a minimum 4-fold rise if baseline is \>1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Day 29

  9. Part C: Percentage of Participants with Seroresponse at Day 29, as Measured by RSV Neutralization Assay

    Seroresponse is defined as post-baseline titer ≥4-fold if baseline is ≥LLOQ or ≥4×LLOQ if baseline titer is \<LLOQ in neutralizing antibody titers measured by RSV neutralization assay, at Day 29.

    Time frame: Day 29

Secondary outcomes

  1. Parts A and B: GMT of Anti-HA Antibodies at Days 121 and 181, as Measured by HAI Assay or Microneutralization Assay

    Time frame: Days 121 and 181

  2. Part C: GMT of Anti-HA Antibodies at Days 57, 121, and 181, as Measured by HAI Assay or Microneutralization Assay

    Time frame: Days 57, 121, and 181

  3. Parts A and B: GMFR of Anti-HA Antibodies at Days 121 and 181, as Measured by HAI Assay or MN Assay

    Time frame: Baseline, Days 121 and 181

  4. Part C: GMFR of Anti-HA Antibodies at Days 57, 121, and 181, as Measured by HAI Assay or MN Assay

    Time frame: Baseline, Days 57, 121, and 181

  5. Part C: Percentage of Participants with Seroresponse at Days 57, 121, and 181, as Measured by HAI Assay

    Seroresponse is defined as a Day 57, 121, or 181 titer \> 1:40 if baseline is \< 1:10 or a minimum 4-fold rise if baseline is \>1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Days 57, 121, and 181

  6. Part C: Percentage of Participants with Seroresponse at Days 57, 121, and 181, as Measured by RSV Neutralization Assay

    Seroresponse is defined as post-baseline titer ≥4-fold if baseline is ≥LLOQ or ≥4×LLOQ if baseline titer is \<LLOQ in neutralizing antibody titers measured by RSV neutralization assay, at Days 57, 121, or 181.

    Time frame: Days 57, 121, and 181

07

Study locations

1 site
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2025, 36 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 36 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Nov 7, 2022
StartActual
Nov 2, 2022
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 13, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05606965
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Nov 2, 2022
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
Nov 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion